阿贝西利|阿贝西利上市!热门CDK4/6靶向药,为何对这类肿瘤尤其有效?( 二 )


致敬生命!
*本文旨在科普癌症新药背后的科学,不是药物宣传资料,更不是治疗方案推荐 。如需获得疾病治疗方案指导,请前往正规医院就诊 。
参考文献:
[1] Treating cancer with selective CDK4/6 inhibitors.Nat Rev Clin Oncol. 2016;13:417-30.
[2] MONARCH 3: Abemaciclib as initial therapy foradvanced breast cancer. J Clin Oncol. 2017;35:3638-46.
[3] MONARCH 2: Abemaciclib in combination withfulvestrant in women with HR+/HER2- advanced breast cancer who had progressedwhile receiving endocrine therapy. J Clin Oncol. 2017;35:2875-84.
[4] MONARCH plus: abemaciclib plus endocrine therapy inwomen with HR+/HER2– advanced breast cancer: the multinational randomized phaseIII study.Ther Adv Med Oncol. 2020 Oct22;12:
[5] Palbociclib andLetrozole in Advanced Breast Cancer. N Engl J Med 2016; 375:1925-1936.
[6] Palbociclib inHormone-Receptor–Positive Advanced Breast Cancer. N Engl J Med 2015;373:209-219.
[7] Progression-FreeSurvival Among Patients With Well-Differentiated or DedifferentiatedLiposarcoma Treated With CDK4Inhibitor Palbociclib. AMA Oncol.2016;2(7):937-940.
[8] Ribociclib as first-line therapy for HR-positive, advanced breastcancer. N Engl J Med. 2016;375:1738-48.

推荐阅读